ENOV · NYSE · Healthcare
Enovis Corporation (ENOV) — Rank #161 by gross profitability (GP/assets 0.36) · ROE -80.2% · Piotroski F-Score 4 / 9.
As-of 2026-10-30 · CIK 0001420800 · all metrics point-in-time as of the filing date.
About
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.
Show moreShow less
It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation.
Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- enovis.com
Company Snapshot
P/S is the primary valuation lens for pre-profit companies.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
7,802
Industry
Medical Devices
Exchange
NYSE
9/12
Flags passed
ENOV fails 2 critical flags
Passes 9 of 12 quality flags, 1 caution
- FAILOperating margin declining
Operating margin lower than prior year
- FAILValuation convergence
EPS declining, shares diluting, and revenue growth decelerating simultaneously
- CAUTIONDilution above 2%
Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation
- PASSGross margin holding
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passBurn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.
Profitability
Does it make money well?
Warning: Operating margin declining · GP/assets 52nd percentile of 41 SIC 38 peers
Gross profitability (GP / assets)
0.36
Primary signal (Novy-Marx).
52nd pctl of 41 SIC 38 peers
Return on equity
-80.2%
Gross margin
59.8%
50th pctl of 41 SIC 38 peers
Revenue growth (YoY)
6.7%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
12.9%
Revenue CAGR (5Y)
14.9%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Cash Flow Health
Is the cash real?
No warning flags · FCF 102% above net income
Free cash flow
$19.92M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
101.7%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.5%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
Caution: Dilution above 2% · net debt $1.27B, F-Score 4/9
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
1.55
8th pctl of 40 SIC 38 peers (best = lowest)
Current ratio
1.98×
23rd pctl of 40 SIC 38 peers
Quick ratio
0.74×
Net cash
-$1.27B
Cash & equivalents minus total debt.
Piotroski F-Score
4 / 9
Fundamental-strength score (0-9).
Valuation
Is the price reasonable?
Warning: Valuation convergence
Capital allocation quality
Composite score
2.3 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports